NYSEAMERICAN:OGEN

Oragenics (OGEN) Stock Price, News & Analysis

Oragenics logo
$0.21 +0.01 (+6.06%)
Closing price 04:10 PM Eastern
Extended Trading
$0.21 0.00 (-0.48%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Oragenics Stock (NYSEAMERICAN:OGEN)

Advanced

Key Stats

Today's Range
$0.18
▼
$0.21
50-Day Range
$0.20
▼
$0.52
52-Week Range
$0.17
▼
$1.11
Volume
671,660 shs
Average Volume
2.57 million shs
Market Capitalization
$947.10 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oragenics is a biotechnology company developing intranasal drug candidates for neurological conditions. Its lead program, ONP-002, is an investigational treatment for concussion, also known as mild traumatic brain injury. The company is studying the candidate’s potential to reach the brain through nasal delivery; it is not an approved treatment.

Oragenics previously focused on oral health and infectious-disease programs, including probiotics and lantibiotics, a class of antimicrobial compounds. The company later shifted its focus toward neurological disorders and obtained rights to develop ONP-002.

AI Generated. May Contain Errors.

Oragenics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

OGEN MarketRank™: 
0.365089940035 of 5 stars

Oragenics scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Oragenics.

  • Price to Book Value per Share Ratio

    Oragenics has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    22.08% of the float of Oragenics has been sold short.
  • Short Interest Ratio / Days to Cover

    Oragenics has a short interest ratio ("days to cover") of 40.07, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Oragenics has recently decreased by 0.15%, indicating that investor sentiment is improving.
  • Dividend Yield

    Oragenics does not currently pay a dividend.

  • Dividend Growth

    Oragenics does not have a long track record of dividend growth.

  • News Sentiment

    Oragenics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Oragenics this week, compared to 0 articles on an average week.
  • Search Interest

    2 people have searched for OGEN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oragenics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.10% of the stock of Oragenics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    18.71% of the stock of Oragenics is held by institutions.

  • Read more about Oragenics' insider trading history.
Receive OGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OGEN Stock News Headlines

My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
Oragenics (NYSEAMERICAN:OGEN) Shares Climb 0.1% - Time to Buy?
Oragenics Inc
See More Headlines

OGEN Stock Analysis - Frequently Asked Questions

Oragenics' stock was trading at $0.78 on January 1st, 2026. Since then, OGEN stock has decreased by 73.1% and is now trading at $0.21.

Oragenics, Inc. (NYSEAMERICAN:OGEN) released its quarterly earnings results on Thursday, November, 12th. The company reported ($0.58) earnings per share (EPS) for the quarter.

Oragenics's stock reverse split on Monday, January 23rd 2023.The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oragenics investors own include Bionano Genomics (BNGO), Jaguar Animal Health (JAGX), Tonix Pharmaceuticals (TNXP), NIO (NIO), Tesla (TSLA), Ocugen (OCGN) and Plug Power (PLUG).

Company Calendar

Last Earnings
11/12/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NYSEAMERICAN:OGEN
Previous Symbol
NYSE:OGEN
CIK
1174940
Employees
3
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($21.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$9.84 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-200.12%
Return on Assets
-146.11%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.50
Quick Ratio
1.50

Sales & Book Value

Annual Sales
$40 thousand
Price / Sales
23.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.24 per share
Price / Book
0.88

Miscellaneous

Outstanding Shares
4,510,000
Free Float
3,786,000
Market Cap
$947.10 thousand
Optionable
N/A
Beta
1.28
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NYSEAMERICAN:OGEN) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners